jump to navigation

FDA Clears MindChild Medical’s Fetal Monitor 10/23/2012

Posted by Morse, Barnes-Brown Pendleton in Client News.
Tags: , , ,
trackback

In February we reported that MBBP client MindChild Medical Inc. had filed for a Pre-Marketing Notification Application (510(k)) with the U.S. Food and Drug Administration for its non-invasive fetal heart rate monitor, MERIDIAN™.  On September 25, MindChild announced that the FDA has cleared MERIDIAN™ and anticipates it entering the U.S. markets in the near future. Bill Edelman, CEO of MindChild, had this to say of the achievement:

We are thrilled to have reached this milestone. MERIDIAN is the first in a series of non-invasive fetal monitor technologies developed by MindChild that are intended to provide the healthcare community enhanced monitoring capabilities for both fetal heart rate and fetal ECG. We anticipate significant clinical interest for this innovative technology in the markets where MERIDIAN will be cleared for commercial distribution.

Congratulations MindChild!

Please view the press release for more information.

Comments»

No comments yet — be the first.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 52 other followers

%d bloggers like this: